503B Bulks List GLP-1: Still a Proposal

The 503B bulks list GLP-1 exclusion is still a proposal in the published record. The Food and Drug Administration (FDA) wants to leave semaglutide, tirzepatide and liraglutide off an ingredient list for compounding—preparing or altering medicines. It does not rewrite the separate rules for a pharmacy preparing medicine for one named patient. GLP-1 medicines act on gut-hormone signals involved in appetite and blood sugar.

What happened to the 503B bulks list GLP-1 proposal?

As of September 10, 2026, the day this article was written, FDA's proposed exclusion remains pending in the published records reviewed here. The agency announced it on April 30, 2026. The formal Federal Register notice, published May 1, proposed leaving all three ingredients off the list after FDA found insufficient evidence of a clinical need for this kind of compounding.

The deadline needs a correction if the April announcement is the version you've seen. That release said June 29; the May notice specified June 30. A June 26 notice extended comments through July 30, 2026. That extended deadline has passed. Closing comments did not turn the proposal into a final decision.

What this means for someone with a prescription

A 503B outsourcing facility is a compounding operation registered with FDA that can supply clinics without a prescription for each named patient. The separate 503B outsourcing facility explainer covers how those facilities work.

“Bulk drug substances” means the active ingredients used to make medicine—the parts that produce its effects. It does not simply mean a large delivery. Under FDA's 503B ingredient rules, the usual routes are an ingredient on the bulks list or a compounded drug on the national shortage list when it is made, distributed and dispensed. Other requirements also apply.

For someone prescribed tirzepatide, the practical question is which pharmacy pathway supplies that prescription. A clinic's name alone doesn't answer it. Neither does the fact that the medicine comes in a vial.

Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved.

Why FDA says there is no clinical need

“Clinical need” here is a legal test for using an ingredient in 503B compounding. It isn't a judgment that people don't need treatment or that paying for it is easy.

FDA's March 2019 guidance sets out two starting questions. Does something about the existing finished medicine make it medically unsuitable for certain patients, and would the proposed preparation address that problem? Must that preparation start with a bulk ingredient, rather than an existing finished medicine?

Cost and ordinary supply backlogs do not establish that need under FDA's interpretation. Convenience alone does not either. The proposal applies that framework to these three drugs; general requests for different strengths or added ingredients did not establish the required need. That is a narrower finding than saying a clinician can never have a reason to consider a compounded formulation.

What it does not change about 503A prescriptions

Section 503A is the separate legal pathway for traditional compounding for an identified patient. It is the prescription route described on this site. The 503B proposal does not amend that section, but 503A still has conditions of its own.

As of September 10, 2026, the day this article was written, FDA's reminder dated April 1, 2026 describes both the individual-prescription requirement and restrictions on regularly making essentially copies, meaning preparations closely matching commercially available medicines. Its policy recognizes a prescriber's documented finding that a change makes a significant difference for that particular patient.

A prescription alone doesn't establish that difference. Adding a vitamin doesn't establish it either. The clinician's reason and the pharmacy's compliance with the remaining requirements both matter. A licensed provider may still prescribe a compounded formulation when the clinical and legal conditions are met; that decision is between the patient and the doctor.

For semaglutide as well as tirzepatide, this distinction separates an individual's prescription from the broader list decision. The GLP-1 shortage court ruling concerns a separate question: FDA's national shortage determinations.

What the prescription route changes

The useful difference is accountability that a patient can verify: an identified prescriber, a licensed dispensing pharmacy, a label stating what's in the vial, and someone responsible for follow-up. An anonymous seller offering medicine without a prescription provides no equivalent clinical relationship.

In a 2024 study by Ashraf and colleagues in JAMA Network Open, researchers received three products from six attempted purchases from online sellers requiring no prescription. Each received sample contained roughly a third more semaglutide than its label stated: 29% to 39% more. Those findings describe three samples, not every online source or licensed pharmacy.

A prescription also needs clear dispensing and counseling. A 2023 report by Lambson and colleagues in the Journal of the American Pharmacists Association described three semaglutide administration errors involving products obtained from compounding pharmacies and an aesthetic spa. Two patients used ten times the intended amount. One reported receiving a vial and syringes without pharmacist counseling.

That small case series cannot tell us how often errors happen. It does explain why a named pharmacy, clear instructions and a way to resolve confusion matter after the visit. These are practical standards for a tirzepatide prescription too; the report did not evaluate tirzepatide or Promise's service.

The FDA telehealth advertising explainer covers how a service should describe those roles and the medication accurately.

What to watch next

The next document that would settle this proposal is FDA's final determination. The May notice says the agency intends to publish that decision in the Federal Register after considering comments; it could retain or change the proposal.

No final determination appeared in the Federal Register searches reviewed through September 10. FDA's current policy index also links to the April 30 proposal rather than a final determination. The proceeding is docket FDA-2018-N-3240, the public file for this decision; a final notice would be the development to look for.

At Promise, a licensed provider reviews every request, and not everyone qualifies. For an individual prescription, the question remains whether the clinician and pharmacy can explain the medical reason, the applicable pathway and who handles follow-up.